Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG – Get Free Report)’s share price gapped down before the market opened on Tuesday. The stock had previously closed at $14.62, but opened at $13.30. Ascentage Pharma Group International shares last traded at $13.1890, with a volume of 850 shares changing hands.
Analysts Set New Price Targets
A number of equities analysts recently issued reports on the stock. JPMorgan Chase & Co. lowered their price objective on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a research report on Thursday, October 8th. BTIG Research reiterated a “buy” rating and set a $48.00 price target on shares of Ascentage Pharma Group International in a report on Tuesday. William Blair started coverage on Ascentage Pharma Group International in a research note on Friday, October 16th. They issued an “outperform” rating for the company. Citizens Jmp assumed coverage on Ascentage Pharma Group International in a report on Tuesday, October 13th. They set a “market outperform” rating and a $35.00 price objective on the stock. Finally, Citigroup started coverage on Ascentage Pharma Group International in a report on Wednesday, October 14th. They set a “buy” rating and a $46.00 price objective on the stock. Two analysts have rated the stock with a Strong Buy rating and eleven have given a Buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $43.44.
Read Our Latest Stock Report on AAPG
Ascentage Pharma Group International Trading Down 0.8%
The company has a quick ratio of 1.18, a current ratio of 1.22 and a debt-to-equity ratio of 1.09. The firm’s 50 day moving average is $15.28 and its two-hundred day moving average is $19.55.
Ascentage Pharma Group International (NASDAQ:AAPG – Get Free Report) last announced its earnings results on Wednesday, August 19th. The company reported ($0.65) earnings per share (EPS) for the quarter. The company had revenue of $22.24 million during the quarter. As a group, sell-side analysts predict that Ascentage Pharma Group International – Unsponsored ADR will post -2.43 earnings per share for the current fiscal year.
About Ascentage Pharma Group International
Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases. Its research focuses on therapies that target mechanisms involved in programmed cell death, or apoptosis, to help prevent cancer cells from surviving and multiplying. The company’s two approved oncology drugs in China are olverembatinib, used to treat certain forms of leukemia, and lisaftoclax (APG-2575), a BCL-2 inhibitor approved for certain patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.
Read More
- Five stocks we like better than Ascentage Pharma Group International
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
Receive News & Ratings for Ascentage Pharma Group International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascentage Pharma Group International and related companies with MarketBeat.com's FREE daily email newsletter.
